Gland Pharma Q2 FY27: Consolidated PAT up 58% YoY to ₹291 Cr, margins expand, beats Street
PAT +58.29% YoY · revenue +23.32% · margins expanding · beat vs street
₹1,833.59 Cr
+23.32% YoY
₹290.76 Cr
+58.29% YoY
15.28%
+3.6pp YoY
₹17.62
Gland Pharma's consolidated revenue rose 23% YoY to ₹1,834 Cr in Q2 FY27 (quarter ended September 30, 2026), with PAT climbing 58% YoY to ₹291 Cr and EPS at ₹17.62 against ₹11.15 a year ago. Both lines came in ahead of Street consensus (GuruFocus) of ~₹1,769 Cr revenue and ₹17.10 EPS — a beat of roughly 3-4% on each. Sequentially the picture cooled: revenue was up just 2% QoQ and PAT fell 8% QoQ from the June quarter's ₹317 Cr, with EBITDA margin easing to 26% (adj. 27%) from 27% (adj. 28%) and PAT margin slipping to 16% from 18%. The YoY read, not the softer sequential print, is the one that should anchor the verdict here.
Q2 FY-2027 vs prior quarters
The YoY margin expansion — EBITDA margin up from 21% to 26%, PAT margin up ~350bps to 16% — was driven by the CDMO business, which grew 31% YoY to ₹823 Cr (45% of sales) on expanding customer engagements and strategic partnerships, outpacing Critical Injectables' 18% YoY growth to ₹1,011 Cr. Geographically the US remained the engine, up 42% YoY to ₹1,180 Cr (64% of revenue), with Europe up 30% YoY to ₹371 Cr, while India (-42% YoY) and other core/rest-of-world markets all declined — a mix shift toward the higher-margin CDMO/US franchise. R&D spend rose to ₹108 Cr (6% of revenue, from 5%) as the company filed 11 ANDAs with 10 approvals in the quarter (cumulative 399 filed, 350 approved) and launched four molecules — Sugammadex, Erythromycin, Fluorouracil and Atropine sulfate — in the US.
The stock went into the print at ₹3,169.6, up 0.6% over the past month of trading.
What the summary numbers don't show
Standalone PAT of ₹425 Cr sits well above consolidated ₹291 Cr, reflecting the continuing drag from European subsidiaries (Cenexi group) below the standalone level
FY27 constant currency revenue growth 15% (raised from 12-13%); EBITDA margins 30% near-term (raised from 25-26%), targeting 35% long-term. Large USD 90-100M CDMO contract starting CY2029. Next 4-year CAGR ~20%.
— This quarter: beat
Revenue growth of 23% YoY comfortably clears management's FY27 guidance of 15% constant-currency growth (raised twice this year, from 12-13%), but the 26% EBITDA margin still trails the 30% near-term margin target reiterated on the same call — a guidance beat on growth, work-in-progress on margin. Executive Chairman Srinivas Sadu framed the quarter as "another quarter of strong growth... driven by strong execution across our businesses," citing CDMO's 31% YoY growth and a "robust opportunity pipeline" — a framing the numbers support on growth but only partially on margin, which remains below the company's own target. During the quarter the company also disclosed a USFDA inspection at its Dundigal facility concluding with four procedural observations (VSEZ had zero), received USFDA approval for Methylprednisolone injectable, and — just after quarter-end — agreed to subscribe to 60% of Novelstar Pharma Inc. in the US for $21M, adding a step-down subsidiary.
W1
Whether adj. EBITDA margin (26-27% currently) re-accelerates toward management's 30% near-term / 35% long-term targets
W2
Progress on the ~$90-100M CDMO contract slated to start CY2029 and the 15 products in co-development (commercialization targeted FY29)
W3
Contribution of the newly acquired 60% stake in Novelstar Pharma Inc. (US, effective Nov 1, 2026) to future US revenue
Figures converted from ₹ million in source (÷10). No exceptional items in the Q2 FY27 or Q2 FY26 columns (FY26's ₹24.3 Cr New Labour Code provision sits in the Dec-25 quarter/FY26 full-year column only), so YoY PAT growth is unadjusted/clean. Standalone PAT (₹424.9 Cr) exceeds consolidated (₹290.8 Cr) due to European subsidiaries (Cenexi group) consolidated below the standalone level — a recurring feature, not a one-off divergence.
Informational and educational content only. Not investment advice.